Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
Status:
Active, not recruiting
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
This is a randomised double-blind clinical trial. The aim is to compare the efficacy and
mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms',
with the SSRI (selective serotonin reuptake inhibitor) escitalopram for major depressive
disorder (MDD).